Pharmaceutical Technology Editors

ISPE has announced the results of its 2013-2014 International Board of Directors election.

PhRMA reports 452 new medicines are in development for rare diseases, including genetic disorders, neurological conditions, infectious diseases, and autoimmune disorders.

The FDA grants Cornerstone Pharmaceuticals orphan drug designation for CPI-613 for the treatment of myelodysplastic syndrome.

CPhI Worldwide starts off with a conference program on Monday 21 October.

The UK regulatory agency issues statement of noncompliance against Wockhardt?s site in Chikalthana, India and Wockhardt?s contract manufacturer Nestor in the United Kingdom.

Governor Jerry Brown cites physician notification requirements for dispensing biosimilars as premature in the absence of FDA specifications for interchangeability.

Genzyme will build a facility in Massachusetts to expand purification capacity for Fabrazyme (agalsidase beta).

Adeline Siew Scientific Editor of Pharmaceutical Technology and Pharmaceutical Technology Europe talks to Joe Galati, Manager, Toxicology Services, Marvin Faber, Sr. Director, Global Head Environmental Health & Safety (EH&S), and Jeff Dinyer, Director EH&S & Global all from Patheon

MedImmune expands its antibody-drug conjugate capability through acquisition and collaboration.

Challenges in the formulation and manufacturing process of fixed-dose combinations

GT Biologics has been granted orphan drug designation by FDA Office of Orphan Product Development for Thetanix,

OncoMed Pharmaceuticals has been granted its first US patent on its MAbTrap antibody display technology.

Roche plans multimillion biologic manufacturing expansions in California, Switzerland, and Germany.

Recipharm has invested EUR 32 million ($43 million) in its Wasserburg, Germany site to expand lyophilization capacity.

The generic-drug manufacturer Teva Pharmaceutical Industries plans to cut 10% of its workforce.

Vetter is investing $100 million to expand filling capacity in Germany and the United States.

Sartorius announces offer to acquire TAP Biosystems Group, a UK-based company.

Aesica expands aseptic capabilities at its Nottingham, UK site with the acquisition of new pre-filled syringes manufacturing equipment.

Use of a continuous-flow reaction made it possible to scale up a highly exothermic reaction for the production of a key Suzuki−Miyaura coupling reagent.

The need to develop a final formulation process for a parenteral product sensitive to stainless-steel gave Patheon the opportunity to evaluate the potential of single-use technology in fill-finish operations.

Catalent has acquired Relthy Laboratorios in Brazil to expand its South American softgel technology business.

ABC Laboratories plans to move operations of its subsidiary, Morse Laboratories, based in California, to Missouri.

Pfenex modifies its contract with US government for Anthrax vaccine.

AMRI has been awarded a seven-year contract for an active ingredient under clinical evaluation.

Carbogen Amcis has made several investments to increase capabilities in supplying antibody drug conjugates.

Hovione's plant in Portugal has successfully passed its twelfth FDA inspection in 18 months.

3M Drug Delivery will manufacture transdermal patch for ProStrakan.

United Drug's Packaging division rebrands as Sharp Packaging.

Marken announces a new depot in Russia and makes a senior appointment.

The Waters ACQUITY QDa Detector is a mass detector designed to bring high-quality, mass spectral data to chromatographic separations.